The outsourced pharmaceutical manufacturing sector is booming in aggregate, but the benefits are not evenly distributed. The Pharma Letter published an analysis showing that scale advantages are concentrating among larger CDMOs with advanced capabilities—biologics, cell and gene therapy, ADC conjugation, mRNA—while smaller CDMOs focused on traditional small-molecule manufacturing face commoditization, margin compression, and overcapacity. The Iran war supply chain disruptions, Section 232 tariffs, and BIOSECURE Act pressures are all reshaping where and how pharma manufactures, and CDMOs that positioned for these shifts early are outperforming those that did not. Merck bought a WuXi Vaccines facility in Ireland, adding vaccine manufacturing capacity while WuXi continues to divest overseas assets amid BIOSECURE uncertainty. Global pharma trade bodies pressed G7 leaders to put pharmaceutical innovation at the center of their economic agenda. Twelve biotechs have gone public in 2026 with a median raise of approximately $300 million—roughly three times the historical average—confirming the IPO window as the healthiest since 2021. Total 2026 biotech IPO proceeds already surpass $3.6 billion. And Novo Nordisk CEO Mike Doustdar told Fierce Pharma he always believed the company “did actually need to become more competitive.”
The CDMO Landscape: Why the Boom Is Not Lifting All Boats
What Happened: The Pharma Letter published an analysis on June 11 examining how the outsourced manufacturing sector’s growth is concentrating among fewer, larger players.
The Structural Divide
Outsourced manufacturing has become part of the basic infrastructure of the pharmaceutical industry. Large drugmakers use CDMOs for flexibility, specialist capacity that would be too expensive to build internally, and regional supply chain diversification. Smaller biotechs use CDMOs because most cannot afford to build manufacturing plants of their own. The demand side is strong across the board.
But the supply side is bifurcating. CDMOs with advanced capabilities—biologics manufacturing, cell and gene therapy production, ADC conjugation, mRNA synthesis—are seeing the strongest demand and the most pricing power. These capabilities require specialized equipment, clean-room facilities, highly trained personnel, and regulatory expertise that take years and significant capital to build. The companies that invested in these capabilities before the current boom are now reaping the returns.
CDMOs focused on traditional oral solid-dose manufacturing—pills and capsules using well-established chemistry—face a different reality. This segment has overcapacity in certain geographies, particularly in Asia, where generic drug manufacturing has built excess capacity over the past two decades. Pricing pressure is intense. Margins are thin. And the competitive moat is shallow because the manufacturing processes are well understood and replicable.
How Geopolitics Is Reshaping the Map
Three forces are simultaneously restructuring the geography of pharmaceutical manufacturing:
The Iran war has disrupted trade routes through the Strait of Hormuz, driving API supplier price increases (Evonik +15% earlier this year) and forcing Indian API manufacturers to reroute supply at dramatically higher costs. CDMOs with supply chains that avoid the affected corridors have a structural advantage.
Section 232 tariffs take effect July 31 for large companies and September 29 for all others. The tariff framework incentivizes domestic U.S. manufacturing by imposing costs on imported pharmaceutical products. CDMOs with U.S.-based facilities—including CordenPharma (which acquired AmbioPharm’s South Carolina peptide plant) and Hikma (investing $267 million in Ohio)—are positioned to benefit as pharma companies seek tariff-advantaged supply.
The BIOSECURE Act creates regulatory uncertainty for CDMOs with Chinese ownership or significant Chinese operations. WuXi’s divestiture program is the most visible manifestation: the company is selling international assets as its U.S.-facing business model faces pressure. Western buyers are acquiring that capacity at what may prove to be favorable valuations.
The combined effect of these three forces is a geographic redistribution of manufacturing capacity from Asia and the Middle East toward the United States and Europe. CDMOs positioned in the right geographies with the right capabilities are experiencing a tailwind that traditional small-molecule manufacturers in Asia are not.
Merck Buys WuXi Vaccines Facility in Ireland
What Happened: Merck acquired a WuXi Vaccines manufacturing facility in Ireland, adding vaccine production capacity in Europe.
Why This Deal Matters
WuXi has been divesting international assets as its U.S.-facing business model faces regulatory pressure from the BIOSECURE Act and broader political scrutiny of Chinese pharmaceutical manufacturing. While WuXi is not directly named in the BIOSECURE legislation, the regulatory uncertainty has prompted a strategic restructuring: divest overseas facilities, focus on the Chinese domestic market, and let Western buyers absorb the international capacity.
For Merck, the Ireland facility provides several strategic advantages. It adds vaccine manufacturing capacity at a time when Merck’s pipeline is expanding beyond traditional small molecules into biologics, ADCs (sac-TMT manufacturing needs), and potentially vaccines. The facility sits in an EU jurisdiction with established regulatory frameworks, favorable corporate tax treatment, and no tariff exposure to either U.S. Section 232 or Chinese regulatory risk. And the acquisition comes from a motivated seller, which typically means favorable transaction economics.
The deal also illustrates a broader pattern in 2026: Western pharmaceutical companies acquiring manufacturing assets that Chinese companies are divesting under political pressure. The assets themselves—facilities, equipment, trained personnel, regulatory licenses—retain their value regardless of the geopolitical dynamics that prompted the sale. The buyer gets high-quality capacity. The seller gets cash and simplified operations. The BIOSECURE Act, intended to reduce Chinese influence in pharmaceutical manufacturing, is inadvertently creating acquisition opportunities for the Western pharma companies it was designed to protect.
Pharma Trade Bodies Press G7 on Innovation Agenda
What Happened: Global branded drug trade bodies urged G7 leaders to put pharmaceutical innovation at the center of their economic agenda ahead of the summit.
Why This Matters: The statement called for policies favorable to R&D investment, intellectual property protection, and regulatory harmonization. The push comes as pharma companies navigate competing policy pressures from multiple directions simultaneously: U.S. tariffs and MFN pricing, EU healthcare reforms (Germany’s pricing initiative prompted Lilly and Boehringer to each withdraw more than $1 billion), and Chinese regulatory assertiveness (Decree No. 834).
The industry’s message to the G7 is essentially: innovation requires investment, investment requires returns, and returns require policy environments that do not compress margins from every direction at once. Whether G7 leaders act on this message or treat it as routine industry lobbying will depend on whether the pharmaceutical supply chain disruptions (Iran war, BIOSECURE, tariffs) have elevated pharma manufacturing to a genuine national security concern in the minds of policymakers.
Separately, Pfizer is weighing additional investment in Germany even as peers have pulled back. Pfizer’s willingness to invest where competitors are withdrawing could give it a competitive positioning advantage in Europe’s largest pharma market—or it could reflect a different assessment of how the reform will actually be implemented. The German pharmaceutical market generates more revenue than any other European country, and a company that maintains manufacturing and R&D presence while competitors withdraw could capture long-term strategic advantages in regulatory relationships, government contracting, and physician engagement that are difficult to rebuild once abandoned.
The divergence between Pfizer’s approach and the Lilly/Boehringer approach highlights that pharmaceutical companies are making fundamentally different strategic bets on the same policy environment. Pfizer may be calculating that the reform will be watered down during implementation. Lilly and Boehringer may be calculating that the reform signals a structural shift in European pricing that justifies redirecting capital to more favorable markets. Both cannot be right. The outcome will provide a real-world case study in how pharmaceutical companies should respond to pricing reform threats—engage or withdraw.
12 Biotechs Have IPO’d in 2026 at a Median of $300M
What Happened: BioPharma Dive reported that a dozen drugmakers have gone public in 2026, raising a median of approximately $300 million each. Total IPO proceeds exceed $3.6 billion.
Why the IPO Market Looks Different Than It Used To
The median raise of $300 million is approximately three times the historical average for biotech IPOs. Key 2026 debuts include Kailera ($625 million), Parabilis ($475 million terms), Odyssey ($304 million), Generate:Biomedicines, Seaport Therapeutics, and Hemab Therapeutics.
The structural shift is clear: companies are staying private longer, raising more venture capital before going public, and entering the public market with more advanced pipelines, validated platforms, and in many cases existing pharma partnerships (Kailera/Lilly, Parabilis/Regeneron). The companies IPO-ing in 2026 are not early-stage startups testing the waters—they are well-capitalized businesses with clinical data and strategic validation.
This benefits public market investors because there is more data to evaluate before the IPO. But it also reduces the number of IPO opportunities because fewer companies need public capital—the venture market is providing enough funding for many biotechs to reach late clinical stages privately.
The $3.6 billion in total proceeds in under six months represents the strongest biotech IPO market since 2021. The window’s health matters for the entire biotech ecosystem: it provides liquidity for venture investors, enables early employees to realize value, and funds the late-stage development that produces the acquisition targets large pharma companies depend on.
Novo CEO: “We Did Actually Need to Become More Competitive”
Novo Nordisk CEO Mike Doustdar told Fierce Pharma he always believed the company “did actually need to become more competitive.” The comment reinforces the strategic urgency behind Novo’s recent moves: the oral Wegovy launch that captured 65% of new obesity starts, the ADA data presentations defending semaglutide’s position, and the pursuit of pipeline diversification beyond the semaglutide franchise.
The acknowledgment is significant because it signals internal recognition at Novo that the GLP-1 competitive landscape has fundamentally changed. Lilly’s Foundayo just beat semaglutide head-to-head in T2D trials at ADA. Retatrutide delivered 28.3% weight loss, exceeding anything semaglutide can achieve. Multiple new entrants are approaching the market. Doustdar’s candor suggests that Novo is not underestimating the competitive threat—it is building a response that goes beyond incremental improvements to its existing franchise.
New Launches: Ethyreal Bio and Orionis/Novartis
Two additional developments round out the week. Ethyreal Bio launched with $101 million in funding on June 10 to develop an antibody therapy for thyroid disease, targeting an autoimmune-driven thyroid condition with limited current treatment options. The launch adds to the steady stream of new biotech company formations in 2026, reflecting the favorable capital environment that is also producing record IPO activity.
Separately, Orionis Biosciences signed a molecular glue collaboration with Novartis. Molecular glues are small molecules that redirect the cell’s protein degradation machinery to destroy disease-causing proteins. The modality has attracted significant pharma interest following the clinical success of cereblon modulators (BMS’s mezigdomide CELMoD platform) and is viewed as a next-generation approach to targeting proteins that have historically been considered “undruggable”—meaning they lack the binding pockets that traditional small molecules require. Novartis’s investment in molecular glue technology through the Orionis collaboration signals that the modality is moving from academic curiosity to industrial-scale drug development, joining ADCs, bispecifics, and in vivo CAR-T as the emerging therapeutic platforms of 2026.
Strategic Themes
1. The CDMO Sector Is Bifurcating into Capability Haves and Have-Nots
Advanced capabilities (biologics, CGT, ADC, mRNA) command premium pricing and strong demand. Traditional small-molecule manufacturing faces overcapacity and margin compression. The Iran war, Section 232, and BIOSECURE are accelerating this divergence by favoring CDMOs in the right geographies with the right capabilities. The CDMO companies that will thrive in the second half of 2026 and beyond are those that invested in advanced manufacturing before the current demand wave—not those scrambling to build it now.
2. WuXi’s Divestitures Are Creating Acquisition Opportunities for Western Pharma
The BIOSECURE Act’s unintended consequence: Chinese CDMOs selling high-quality international facilities to the Western companies the legislation was designed to protect. Merck’s Ireland acquisition is a specific example. More divestitures are likely as WuXi AppTec, WuXi Biologics, and WuXi Vaccines continue to restructure. Western pharma and CDMO companies with the capital and strategic interest to acquire these assets are getting quality manufacturing capacity from motivated sellers.
3. The 2026 IPO Market Is the Healthiest Since 2021
$3.6 billion in proceeds from 12 IPOs in under six months. The median raise of $300 million (approximately three times the historical average) reflects a new era of larger, later-stage biotech IPOs. The window is not just open—it is producing the largest and most mature biotech debuts in years.
The quality of the companies going public has shifted as meaningfully as the scale. Kailera IPO’d with a Lilly/Hengrui GLP-1 partnership. Parabilis set terms with a Regeneron AHC collaboration already signed. These are not speculative early-stage companies—they are businesses with validated platforms, existing pharma partnerships, and substantial private capital that chose the public market for growth financing rather than survival capital.
For the broader deal ecosystem, a healthy IPO market fuels the venture capital cycle that produces the clinical-stage assets large pharma acquires. Venture investors who can exit through IPOs are more willing to fund new companies, which generates the pipeline of innovation that the $115 billion M&A cycle depends on. The IPO market and the M&A market are not separate phenomena—they are connected nodes in the same capital ecosystem.
4. Novo’s Competitiveness Admission Is the Right Response to Lilly’s ADA Data
Doustdar saying Novo needed to become more competitive is not a weakness—it is a strategic signal that the company is not complacent. With Foundayo beating semaglutide in T2D and retatrutide delivering 28.3% weight loss, Novo cannot rely on its first-mover advantage indefinitely. The question is whether Novo’s response (oral Wegovy, higher-dose formulations, pipeline diversification) can match the pace of Lilly’s three-tier portfolio buildout and 12-deal acquisition campaign.
Frequently Asked Questions
What is happening in the CDMO sector?
The outsourced manufacturing boom is concentrating among larger CDMOs with advanced capabilities (biologics, CGT, ADC, mRNA). Smaller CDMOs focused on traditional manufacturing face margin pressure. Geopolitical forces (Iran war, Section 232, BIOSECURE) are reshaping manufacturing geography toward the U.S. and Europe.
What did Merck acquire from WuXi?
A WuXi Vaccines manufacturing facility in Ireland. The deal adds vaccine production capacity in an EU jurisdiction with no U.S. or Chinese tariff exposure. WuXi is divesting international assets amid BIOSECURE Act uncertainty.
How healthy is the biotech IPO market?
Twelve biotechs have IPO’d in 2026 with a median raise of approximately $300M (3x historical average). Total proceeds exceed $3.6B, already doubling 2025’s full-year total. Key names include Kailera ($625M), Parabilis ($475M), and Odyssey ($304M).
What did the Novo CEO say?
Mike Doustdar told Fierce Pharma he always believed Novo “did actually need to become more competitive.” The comment signals internal recognition that the GLP-1 competitive landscape has changed with Lilly’s Foundayo T2D superiority and retatrutide’s 28.3% weight loss.
What are pharma trade bodies asking from the G7?
Policies favorable to R&D investment, IP protection, and regulatory harmonization. The push reflects the industry’s concern that competing policy pressures from the U.S. (tariffs, MFN), EU (pricing reforms), and China (Decree 834) are compressing margins simultaneously.
When is BIO International?
June 22 to 25 in San Diego. The industry’s largest partnering event. Two weeks out.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
CDMO Landscape. We identify which CDMOs are winning the outsourced manufacturing race, why scale and advanced capability are the new differentiators, and how the Iran war, Section 232, and BIOSECURE are reshaping the competitive map.
WuXi Divestitures. We analyze what Merck’s Ireland acquisition signals about the BIOSECURE-driven reshuffling of global pharma manufacturing, assess how many more WuXi assets are likely to be divested, and evaluate the acquisition opportunity for Western buyers.
IPO Market Health. We compile the full 2026 IPO scorecard, analyze why $300M median raises confirm the window is structurally open rather than temporarily, and assess what the shift toward larger, later-stage IPOs means for public market biotech investing.
Plus: Novo competitiveness strategy, Pfizer German investment analysis, G7 innovation agenda, Orionis/Novartis molecular glue, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
